Optimizing the immunogenicity of HIV prime-boost DNA-MVA-rgp140/GLA vaccines in a phase II randomized factorial trial design

BACKGROUND: We evaluated the safety and immunogenicity of (i) an intradermal HIV-DNA regimen given with/without intradermal electroporation (EP) as prime and (ii) the impact of boosting with modified vaccinia virus Ankara (HIV-MVA) administered with or without subtype C CN54rgp140 envelope protein a...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:PLoS One
Hlavní autoři: Viegas, Edna O., Kroidl, Arne, Munseri, Patricia J., Missanga, Marco, Nilsson, Charlotta, Tembe, Nelson, Bauer, Asli, Joachim, Agricola, Joseph, Sarah, Mann, Philipp, Geldmacher, Christof, Fleck, Sue, Stöhr, Wolfgang, Scarlatti, Gabriella, Aboud, Said, Bakari, Muhammad, Maboko, Leonard, Hoelscher, Michael, Wahren, Britta, Robb, Merlin L., Weber, Jonathan, McCormack, Sheena, Biberfeld, Gunnel, Jani, Ilesh V., Sandström, Eric, Lyamuya, Eligius
Médium: Artigo
Jazyk:Inglês
Vydáno: Public Library of Science 2018
Témata:
Research Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6264478/
https://ncbi.nlm.nih.gov/pubmed/30496299
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0206838
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky